First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial
- Hye Ryun Kim
- , Shunichi Sugawara
- , Jong Seok Lee
- , Jin Hyoung Kang
- , Naoki Inui
- , Toyoaki Hida
- , Ki Hyeong Lee
- , Tatsuya Yoshida
- , Hiroshi Tanaka
- , Cheng Ta Yang
- , Makoto Nishio
- , Yuichiro Ohe
- , Tomohide Tamura
- , Nobuyuki Yamamoto
- , Chong Jen Yu
- , Hiroaki Akamatsu
- , Shigeru Takahashi
- , Kazuhiko Nakagawa
- Yonsei University
- Sendai Kousei Hospital
- Seoul National University
- Hamamatsu University School of Medicine
- Aichi Cancer Center Hospital and Research Institute
- Chungbuk National University
- National Cancer Center Japan
- Niigata Cancer Center Hospital
- Chang Gung Memorial Hospital
- Japanese Foundation for Cancer Research
- St. Luke's International Hospital
- Wakayama Medical University
- National Taiwan University
- Ono Pharmaceutical Co., Ltd.
- Kindai University
Research output: Contribution to journal › Article › peer-review
17
Scopus
citations